Get Your Free Mesothelioma Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Genetic testing for mesothelioma is key for early detection, treatment and survival. Research suggests genetic risk factors, such as a mutated BAP1 gene, increase the likelihood an individual will develop mesothelioma as a result of asbestos exposure.
Written by Karen Selby, RN | Medically Reviewed By Dr. Jeffrey Velotta | Edited By Walter Pacheco | Last Update: December 4, 2024
Research shows that some genes might raise the risk of mesothelioma after asbestos exposure. The risk also depends on how much and how long someone is exposed to asbestos. Some genes might explain why some people are more prone to diseases from asbestos
Mesothelioma can occur in people after minimal exposure to asbestos. The most well-known mesothelioma genetic risk factor is BAP1, a tumor-suppressor gene. Several studies show a BAP1 mutation is a risk factor for mesothelioma.
About 12% of mesothelioma cases develop in people with mutations of BAP1 or other genes. Prevention is crucial for those at risk.
In 2007, scientists studied families in an area of Turkey known for asbestos exposure. They found that a BAP1 gene mutation increases the risk of mesothelioma.
After several years of studying a unique mesothelioma epidemic in Cappadocia, Turkey, we noted that in certain families, up to 50% of family members developed mesothelioma. We demonstrated that susceptibility to mesothelioma was transmitted genetically from one generation to the next.
Another study evaluated two U.S. families with high incidences of mesothelioma. Researchers found a BAP1 mutation in every family member with mesothelioma. Additional research has also linked this gene to mesothelioma..
Mesothelioma is not hereditary. However, some people inherit genes that raise their risk after asbestos exposure. For instance, those with a mutated BAP1 gene face a higher risk if exposed to asbestos, the main cause of mesothelioma.
The BAP1 gene controls calcium in cells. If it’s damaged or mutated, calcium levels fall. This raises cancer risk from substances like asbestos. For those with a BAP1 mutation, asbestos exposure raises mesothelioma risk.
Get Your Free Mesothelioma Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Some researchers believe that fixing genetic mutations may help prevent and treat mesothelioma. For example, a 2017 Nature study found that a normal BAP1 gene and repaired calcium channels led to positive chemotherapy results.
You cannot fix something unless you know what is broken. We discovered the first, and so far, only known biological mechanism that makes some people more susceptible. The fixed channels should be able to prevent cancer in people who have inherited the mutation. It can also help treat cancers whose tumor cells have developed mutations.
A clinical trial set to wrap up in 2026 is testing a drug called TAK-500 that targets immune system genes. The hope is that the drug will stimulate the immune system to attack mesothelioma.
In 2018, a clinical trial tested the immunotherapy drug olaparib, or Lynparza. Researchers aimed to see how well it worked for pleural and peritoneal mesothelioma.
Lynparza is a protein inhibitor effective against breast and ovarian cancers. It targets the BRCA gene, a close relative to BAP1. Researchers hoped for similar results in mesothelioma, but it proved ineffective.
Doctors have a hard time predicting how long mesothelioma patients will live. Genetic testing may improve estimates of how long someone may survive with mesothelioma.
A 2022 research study noted that DNA could show a patient’s resistance to chemotherapy drugs. Another 2022 study looked at the effects of BAP1 status on survival. About 60% of participants had BAP1 loss. In those patients, median survival after chemo was longer by almost 13 months.
The Proceedings of the National Academy of Sciences looked at mesothelioma in 2019. They studied how DNA repair genes impact mesothelioma survival. Patients with a DNA suppressor gene mutation survived longer than those without.
With Mutation | Without Mutation |
---|---|
7.9-year median survival | 2.4-year median survival |
BAP1 increases the risk of developing mesothelioma but also improves long-term survival. Research shows they respond better than the average patient. This might mean people with this mutation could get more aggressive treatment.
Try our new clinical trials search tool to find active trials near you. Get help enrolling today.
Find a Clinical TrialOngoing studies continue to explore the link between gene mutations and cancer. Researchers hope to learn more about what causes tumors to grow and mutate.
Some drugs and treatments can prevent genetic mutations and treat cancer. Gene therapy is a field of medicine that aims to repair genes to prevent and treat tumors.
Researchers in Belgium studied a family with a history of mesothelioma in 2014. Investigators ruled out BAP1 as a cause of mesothelioma in this family. They identified 11 other possible gene mutations.
The most prominent mutation was RBM15. The study could not prove these mutations caused mesothelioma or other cancers.
Many mutations correlate with other cancers. Gaining a better understanding of these mutations helps researchers personalize treatment further. Several drugs that target those mutations already exist.
This Page Contains 12 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
Selby, K. (2024, December 4). Genetic Risk Factors for Mesothelioma. Asbestos.com. Retrieved December 5, 2024, from https://www.asbestos.com/mesothelioma/genetic-factors/
Selby, Karen. "Genetic Risk Factors for Mesothelioma." Asbestos.com, 4 Dec 2024, https://www.asbestos.com/mesothelioma/genetic-factors/.
Selby, Karen. "Genetic Risk Factors for Mesothelioma." Asbestos.com. Last modified December 4, 2024. https://www.asbestos.com/mesothelioma/genetic-factors/.
A medical doctor who specializes in mesothelioma or cancer treatment reviewed the content on this page to ensure it meets current medical standards and accuracy.
Please read our editorial guidelines to learn more about our content creation and review process.
Dr. Jeffrey Velotta is an experienced thoracic surgeon and pleural mesothelioma specialist at Kaiser Permanente Oakland Medical Center in California. Velotta also serves as an assistant professor at the University of California, San Francisco.
Mesothelioma Center - Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.